| 摘要 |
This invention encompasses compounds of the formula (I) where X1, X2, and X3, independently represents substituents of formula (A) and the pharmaceutically acceptable salts thereof wherein C = N or O; D = nothing when C = O, H, lower straight or branched chain alkyl having 1-6 carbon atoms, a methylene unit incorporated into a ring connected with F (also a methylene) as in the cases of pyrrolidine, pyrrolidone, piperidine, and piperidone; E = O or H2; o = 0 or 1; F = straight or branched chain lower alkyl having 1-6 carbon atoms, aryl, aryl substituted with halogen, straight or branched chain lower alkyl having 16 carbon atoms, heteroaryl - preferably selected from the group consisting of 2-, 3-, or 4-pyridyl, 2-pyrazyl 2-, or 3-thienyl, 2-pyrazinyl, 2-, 3-, or 4quinolyl, 1-, 3-, or 4-isoquinolyl, 2-quinoxalyl, 3-, or 4-cinnolyl, heteroaryl substituted with halogen, hydroxy, straight or branched chain lower alkyl having 1-6 carbon atoms, straight or branched chain lower alkoxy having 1-6 carbon atoms; and also wherein A and T represent organic or inorganic substituents, n is 1, 2, or 3, m is 2, 3, or 4, R1-R4 are hydrogen or organic substituents, and B is nitrogen, carbon, sulfur or oxygen, useful in the diagnosis and treatment of feeding disorders such as obesity and bulimia and cardiovascular diseases such as essential hypertension and congestive heart failure due to the binding of these compounds to human neuropeptide Y1 receptors.
|
